Novakand Pharma AB (FRA:3EE0) Total Operating Expense: €2.70 Mil (TTM As of Dec. 2025)


What is Novakand Pharma AB Total Operating Expense?

Novakand Pharma AB FRA:3EE0 Total Operating Expense is €2.70 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Novakand Pharma AB's Total Operating Expense for the three months ended in Dec. 2025 was €0.46 Mil. Novakand Pharma AB's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €2.70 Mil.

Novakand Pharma AB Total Operating Expense Related Terms

Novakand Pharma AB Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Novakand Pharma AB's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novakand Pharma AB Total Operating Expense Chart

Novakand Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.57 4.79 5.96 4.01 2.72

Novakand Pharma AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 1.20 0.58 0.47 0.46

Novakand Pharma AB Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €2.70 Mil mean?
Novakand Pharma AB (FRA:3EE0) has a Total Operating Expense of €2.70 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Novakand Pharma AB and its competitors.
Is Novakand Pharma AB's Total Operating Expense too high?
Novakand Pharma AB's current Total Operating Expense is €2.70 Mil.
How does Novakand Pharma AB's Total Operating Expense compare to VRTX and REGN?
Novakand Pharma AB's Total Operating Expense of €2.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Novakand Pharma AB and its competitors. Novakand Pharma AB's current Total Operating Expense is €2.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novakand Pharma AB stock overvalued right now?
Novakand Pharma AB (FRA:3EE0) has a current Total Operating Expense of €2.70 Mil. The current Total Operating Expense is €2.70 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Novakand Pharma AB (FRA:3EE0), the current Total Operating Expense is €2.70 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Novakand Pharma AB Business Description

Address Nanna Svarts vag 4, Solna, SWE, 171 65
Novakand Pharma AB is developing a new class of innovative drugs focusing on inflammatory diseases and cancer. The company is developing a new class of small molecule drugs that control disease promoting immune cells with precision, by targeting the fractalkine axis.